Trinity Biotech
TRIB
92 hedge funds and large institutions have $269M invested in Trinity Biotech in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 14 closing their positions.
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
3% more capital invested
Capital invested by funds: $260M → $269M (+$8.66M)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
1% less funds holding
Funds holding: 93 → 92 (-1)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
37% less call options, than puts
Call options by funds: $492K | Put options by funds: $778K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$6.33M |
| 2 |
Millennium Management
New York
|
+$5.4M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$4.54M |
| 4 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
+$4M |
| 5 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$3.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$10.2M |
| 2 |
PC
Pier Capital
Stamford,
Connecticut
|
-$4.56M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.92M |
| 4 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$2.63M |
| 5 |
Renaissance Technologies
New York
|
-$1.81M |
TRIB Hedge Fund Activity: Q4 2014 in Review
92 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2014, worth a combined $269M — up 3.3% from $260M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TRIB positions and 14 closed out — a net gain of 2 holders — while 31 added to existing stakes and 31 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $6.33M. The largest seller was Chartwell Investment Partners, exiting entirely with an estimated $10.2M sold.
- 92 institutional investors held Trinity Biotech (TRIB) as of Q4 2014, down from 93 in Q3 2014.
- Funds reported $269M of Trinity Biotech stock for Q4 2014, up 3.3% quarter-over-quarter.
- 16 funds opened new Trinity Biotech positions in Q4 2014 and 14 closed out, a net change of +2 holders.
- The largest Trinity Biotech buyer in Q4 2014 was Kennedy Capital Management, an estimated $6.33M added.
- The largest Trinity Biotech seller in Q4 2014 was Chartwell Investment Partners, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2014.